The board of directors of Simulations Plus Inc (Nasdaq:SLP) declared the company's next ongoing quarterly dividend of USD0.06 per share of its common stock, it disclosed on Monday.
This cash dividend is due on 1 November 2019 to shareholders of record as of 25 October 2019.
Simulations Plus is a drug discovery and software company that provides both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease.
In addition, the company's software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development